

Bristow goes with technology and selects the stock to watch in 2022

Welcome to 2022! I'm cautiously optimistic that this will be the year we get to put Covid in the rear-view mirror and get on with life without always waiting for the next shoe to drop (or a new variant to take hold). I'm happy to put 2021 in the history books and anticipate the bright future that could be. In that vein, I'd like to look ahead to what I think could be an exciting story for 2022. Now don't get me wrong, I'm not saying this is my top pick or suggesting it will go up. This is simply my perspective on a company that has a lot going on that could be rewarded by the market this year.

The path of least resistance, after this week's market action, would be to pick a uranium stock. Between how this group performed in 2021 and even more impressively, the first couple of trading days of 2022, it would certainly make for an easy article to write. I'm also a fan of junior base and precious metal mining companies, especially ones with plenty of results pending, but not today. The future is technology, so my exciting stock for 2022 is a technology company that posted a respectable 35% return in 2021 but is well positioned for 2022. It also happened to evolve out of a junior mining exploration company so it's the best of both worlds.

If you haven't figured out what company I'm talking about yet, it's Zentek Ltd. (TSXV: ZEN), formerly known as ZEN Graphene Solutions Ltd. There is so much going on at Zentek it's hard to know where to start. The Company currently describes itself as an IP development and commercialization company focused on next-gen healthcare solutions in the areas of prevention, detection and treatment. Zentek is currently focused on commercializing ZENGuard™, a patent-pending coating shown to

have 99% antimicrobial activity, including against COVID-19, and the potential to use similar compounds as products against infectious diseases. The Company also has an exclusive agreement to be the global commercializing partner for a newly developed aptamer-based rapid pathogen detection technology. But that's just the tip of the iceberg in my opinion.

The near-term catalyst is all about the antimicrobial coating ZENGuard™, which was developed as a virucidal graphene-oxide ("GO") based compound to be applied as a coating onto fabrics, which included personal protective equipment such as face masks in an effort to increase protection afforded by such products. In September 2021 the Company received Health Canada approval for the sale of ZENGuard™ coated masks and entered into a binding definitive license and supply agreement with Trebor Rx Corp. for the supply of ZENGuard™ to coat face masks and potentially other health care products. To date, Trebor has purchased, and the Company has delivered, quantities of ZENGuard™ coating sufficient for the production of 10,000,000 masks currently done via third parties. However, development is underway of the Company's industrial scale facility to produce ZENGuard™ and to coat materials. The Company anticipates assembly and installation of the industrial scale production equipment to be completed during Q1 2022, at which point production is expected to commence while commissioning, optimization and production ramp-up occurs over the following two to three months. Once this industrial process is in operation, the Company expects the production capacity of ZENGuard™ to increase significantly.

Zentek recently closed a bought deal public offering and a non-brokered private placement for aggregate proceeds of C\$33 million to assist in the build out of their facility as well as research and development, acceleration of business growth opportunities and working capital. Other growth opportunities include the development of a new carbon-based nanotechnology-enhanced icephobic coating to reduce ice accretion. The

Company anticipates applications for aircraft, wind turbines, ocean vessels, and building structures to increase safety and efficiency outcomes in ice-forming weather conditions. In late November Zentek announced it had been awarded an R&D test contract through the Innovation Solutions Canada Testing Stream to test ZENGuard™ coated HVAC filters with interest from 3 different units within the National Research Council of Canada. Other innovations include the development of a stable diesel fuel additive, which increased the performance of diesel fuel by up to 10% in initial testing.

There is an awful lot going on at Zentek so I would encourage you to go check out their website to learn more because I've only scratched the surface of this stock to watch in 2022. Granted it's not a small cap with a market cap of roughly \$466 million after the closing of the latest capital raise earlier this week. Nevertheless, there are plenty of near-term catalysts with having their own production facility operational in the next few months and some pretty creative and unique opportunities being developed to propel this Company into the future.

Zentek is well positioned to commercialize several revolutionary nanotech graphene health products in 2022

Zentek Ltd. (TSXV: ZEN) (formerly ZEN Graphene Solutions Ltd.)

is a trail blazing company in the world of nanotechnology and graphene, particularly in the healthcare sector. That is because not only does it make its own graphene but Zen has also partnered with other companies to expand the uses of graphene in areas such as (graphene coated) masks clothing, and other PPE, as well as COVID-19 rapid saliva tests, graphene colloidal antiviral/bacterial/fungal detection, and, hopefully, improved air purifiers, and air conditioning systems using graphene filtration.

Zentek summarizes this by saying that “Nanotechnology and graphene have the potential to protect against pathogens, detect and treat disease, clean our water, make building materials stronger and produce cleaner energy. With almost limitless potential to improve people’s lives, we are uniquely positioned to create significant value through our next-generation healthcare solutions and beyond.”

Zentek is currently focusing on commercializing into health care prevention, detection, and treatment

zentek

IP development and commercialization company focused on next-gen, nanotechnology-enabled healthcare solutions

Development pipeline is robust with opportunities in three primary verticals:



ZENGuard™ for PPE & indoor air quality markets



Aptamer-based rapid detection for numerous pathogens



Antimicrobial compound as a therapeutic and healthcare product

Source: Zentek Company presentation

Zentek’s vision is for a healthier and safer world through nanotechnology, and its mission is to develop innovative

nanotechnologies, with their partners, that improve people's lives. What a great basis to grow a company from.

Zentek's stock price has risen 281% over the past year after more than quadrupling the year before. From the March 1, 2020 low of C\$0.30 the stock **has risen a whopping 20.7x**, now sitting at C\$6.20. Tesla and some junior lithium stocks are the only stocks I know that have achieved a 20x return in the past 2 years. This puts Zentek up there with the most elite performers on the stock market in recent times.

What's next for Zentek

- **A Nasdaq listing** – On October 13, 2021, Zentek (then ZEN Graphene Solutions) announced that it has submitted an application to list its common stock on The Nasdaq Capital Market® (“Nasdaq”) and that it has retained Donohoe Advisory Associates, LLC, to assist with the listing process. That process is ongoing with no listing date yet announced.
- **ZENGuard™ international patent application to complete soon.** ZENGuard™ is a graphene-silver ‘coating’ with 99% antimicrobial activity, including against COVID-19. Zentek is commercializing ZENGuard™ with mask manufacturer, Trebor Rx, to produce masks, filters and gloves. ZENGuard™ is Health Canada approved. Zentek's coating can also be used on all types of personal protective equipment including masks, gloves, clothes, and shields to reduce the spread of pathogens including COVID-19. Similar products can be used in air purification systems. There is also the potential (if approved) to use similar compounds as pharmaceutical products against infectious diseases.
- **Zentek's Pathogen Detection Technology (aptamer-enabled) initially for COVID-19 to be launched by Q1, 2022.** Zentek has the worldwide exclusive rights to

commercialize a rapid, saliva-based COVID-19 antigen testing technology. The key differentiating factor here is that the test can detect much lower quantities of virus compared to other tests, thereby being able to potentially detect low viral loads at the early stages of infection when the patient may be asymptomatic. The test is exceptionally accurate (similar to current PCR tests), saliva-based, affordable, scalable and provides results in under 10 minutes. The test still requires final Health Canada and FDA approval. Zentek recently announced the development of an improved aptamer with a higher binding affinity for the COVID-19 Delta variant as well as reduced result production time of the aptamer-based sensor from 18 hours to 30 minutes with more consistent results. Zentek also announced this month that it “has been selected as one of three technologies for phase 1 of the Innovation Solutions Canada (ISC) challenge to develop a portable detection device for SARS-CoV-2 in wastewater. ZEN has received a \$148,000 award from ISC to develop its first prototype.”

Zentek CEO, Greg Fenton, recently stated: “In collaboration with our partners, including Dr. Li and his entire McMaster team, **we have made tremendous progress advancing our aptamer-based rapid detection platform toward commercialization.** A key aspect of the technology is its adaptability through the production of new aptamers to detect different pathogens leveraging the existing platform – and the process of building out this aptamer and disease-detection library is well underway with our colleagues at McMaster.”

ZENGuard™ has enormous potential to scale up from current capacity of coatings for 32 million masks per month to a potential ~800 million masks per month by Q1, 2022



Note: Season flu and tuberculosis visuals for illustration purposes only and have not yet been tested

7

Source: Zentek Company presentation

Closing remarks

Zentek has come a long way in the past 2 years with enormous technological progress in its graphene based nanotechnology products with a renewed health focus to prevent, detect, and, hopefully, soon treat pathogens, including COVID-19. This has been achieved via a number of collaborations, partnerships, patents, and approval by regulatory bodies.

The result of all these efforts should now start to show in 2022 as Zentek's commercial rollout of its innovative nanotech graphene products gains speed, led by its revolutionary ZENGuard™ coating and the company's rapidly advancing Pathogen Detection Technology collaboration.

Zentek trades on a market cap of C\$551 million and continues to outperform the market.

Disclosure: The author is long ZEN Graphene Solutions (TSXV: ZEN).

Greg Fenton on the significant medical market interest in Zentek's ZENGuard™ nanotech coatings, plus its new carbon-based icephobic coating

In a recent InvestorIntel interview, Tracy Weslosky spoke with Greg Fenton, CEO and Director of Zentek Ltd. (TSXV: ZEN) about Zentek's new icephobic coating to reduce ice accretion on surfaces, and about the significant market interest in their ZENGuard™ coating following its Health Canada approval.

In this InvestorIntel interview, which may also be viewed on YouTube (click here to subscribe to the InvestorIntel Channel), Greg Fenton said that the company's recent change of name from ZEN Graphene Solutions Ltd. to Zentek Ltd. reflects its evolution from a mining company to a technology company, developing intellectual properties. Having recently applied for an up listing to the Nasdaq, Greg said that Zentek is primarily focused on nanotechnology-enabled healthcare solutions, and continues to develop intellectual properties for other industries as well.

To watch the full interview, click here.

About Zentek Ltd.

Zentek is a nanotechnology company developing and commercializing next-gen healthcare solutions in the areas of

prevention, detection and treatment. Zentek is currently focused on commercializing ZENGuard™, a patent-pending coating with 99% antimicrobial activity, including against COVID-19, and the potential to use similar coatings as pharmaceutical products against infectious diseases. The company also has an exclusive agreement to be the global commercializing partner for a newly developed, highly scalable, aptamer-based, rapid pathogen detection technology.

To learn more about Zentek Ltd., [click here](#).

Disclaimer: Zentek Ltd. is an advertorial member of InvestorIntel Corp.

This interview, which was produced by InvestorIntel Corp. (IIC) does not contain, nor does it purport to contain, a summary of all the material information concerning the “Company” being interviewed. IIC offers no representations or warranties that any of the information contained in this interview is accurate or complete.

This presentation may contain “forward-looking statements” within the meaning of applicable Canadian securities legislation. Forward-looking statements are based on the opinions and assumptions of management of the Company as of the date made. They are inherently susceptible to uncertainty and other factors that could cause actual events/results to differ materially from these forward-looking statements. Additional risks and uncertainties, including those that the Company does not know about now or that it currently deems immaterial, may also adversely affect the Company’s business or any investment therein.

Any projections given are principally intended for use as objectives and are not intended, and should not be taken, as assurances that the projected results will be obtained by the Company. The assumptions used may not prove to be accurate and a potential decline in the Company’s financial

condition or results of operations may negatively impact the value of its securities. Prospective investors are urged to review the Company's profile on Sedar.com and to carry out independent investigations in order to determine their interest in investing in the Company.

If you have any questions surrounding the content of this interview, please email info@investorintel.com.

ZEN Graphene's Greg Fenton discusses Health Canada's approval of the 'gold standard' for face masks

In a recent InvestorIntel interview, Tracy Weslosky spoke with Greg Fenton, CEO and Director of ZEN Graphene Solutions Ltd. (TSXV: ZEN) about Health Canada's approval this week of the **ZENGuard™** disposable face mask with the company's biocidal coating.

In this InvestorIntel interview, which may also be viewed on YouTube ([click here to subscribe to the InvestorIntel Channel](#)), Greg said that the graphene based **ZENGuard™** coating on a mask kills airborne pathogens like bacteria, fungi and viruses. Explaining why it is the 'gold standard' for face masks, Greg discusses how as a result of the review, Health Canada has validated that **ZENGuard™**-enhanced surgical masks are safe for use by Canadians.

Responding to the questions on the technology associated with the **ZENGuard™** masks, Greg provides insight into the impact of

this approval and what this means for ZEN Graphene. This includes the application of their biocidal coating in other spaces such as the HVAC market.

To watch the full interview, [click here](#).

About ZEN Graphene Solutions Ltd.

ZEN is a nanotechnology company developing and commercializing next-gen healthcare solutions in the areas of disease prevention, detection and treatment. ZEN is currently focused on commercializing **ZENGuard™**, a patent-pending coating with 99% effective antimicrobial activity against COVID-19, and the potential to use similar compounds as pharmaceutical products against many other infectious diseases. The company also has an exclusive agreement to be the global commercializing partner for a newly developed, highly scalable, aptamer-based rapid pathogen detection technology.

To learn more about ZEN Graphene Solutions Ltd., [click here](#)

Disclaimer: ZEN Graphene Solutions Ltd. is an advertorial member of InvestorIntel Corp.

This interview, which was produced by InvestorIntel Corp. (IIC) does not contain, nor does it purport to contain, a summary of all the material information concerning the “Company” being interviewed. IIC offers no representations or warranties that any of the information contained in this interview is accurate or complete.

This presentation may contain “forward-looking statements” within the meaning of applicable Canadian securities legislation. Forward-looking statements are based on the opinions and assumptions of management of the Company as of the date made. They are inherently susceptible to uncertainty and other factors that could cause actual events/results to differ materially from these forward-looking statements. Additional risks and uncertainties, including those that the

Company does not know about now or that it currently deems immaterial, may also adversely affect the Company's business or any investment therein.

Any projections given are principally intended for use as objectives and are not intended, and should not be taken, as assurances that the projected results will be obtained by the Company. The assumptions used may not prove to be accurate and a potential decline in the Company's financial condition or results of operations may negatively impact the value of its securities. Prospective investors are urged to review the Company's profile on Sedar.com and to carry out independent investigations in order to determine their interest in investing in the Company.

If you have any questions surrounding the content of this interview, please email info@investorintel.com.

ZEN Graphene is changing the world one nanomaterial at a time

Scientists have not unanimously settled on a precise definition of nanomaterials, but agree that they are partially characterized by their tiny size, measured in nanometers. A nanometer is one millionth of a millimeter – approximately 100,000 times smaller than the diameter of a human hair. For a while, nanomaterials were going to save the world by making everything faster, stronger and maybe even higher. But Olympic motto aside, there was a lot of hype about nanomaterials and a decade(s) later not much to show for all that optimism. Or maybe there is if you look in the right places.

Nano-sized particles exist in nature and can be created from a variety of products, such as carbon or minerals like silver, but nanomaterials by definition must have at least one dimension that is less than approximately 100 nanometers. One such company that is making progress in the world of nanomaterials is ZEN Graphene Solutions Ltd. (TSXV: ZEN), despite starting life as a mining company. In fact, the Company still maintains its unique Albany Graphite Project, which provides the company with a potential long-term competitive advantage in the graphene market. The unique genesis of the Albany deposit, resulting in very fine-grained graphite crystallites, yields an ideal graphite precursor material for conversion to high-value graphene, graphene oxide and graphene quantum dots that can be used in a wide variety of applications.

However, don't kid yourself into thinking this is a mining story. It is very much a technology story that has evolved out of the special characteristics of the graphite available at the Albany deposit. ZEN has a broad reach as far as solutions being derived from nanomaterials. Front and center is the ZENGuard™ antimicrobial coating which can be utilized on PPE, filtration media (HVAC filters) and other materials such as paper, cardboard etc. as a preventative 'catch-and-kill' mechanism. The Company has developed a non-toxic, antimicrobial coating that is 99+% effective against numerous pathogens, including COVID-19, with initial testing showing a further 98% effectiveness after 108 days. ZENGuard™ on masks, gloves and other PPE to protect front-line workers, the public and reduce the spread of pathogens (including and beyond COVID-19) has an estimated global market of US\$52 billion. While the potential market for ZENGuard™ on air filters to kill airborne pathogens in homes, schools, hospitals and commercial and industrial spaces is estimated at US\$66 billion. Not a bad starting point.

As a spin-out from the focus on everything COVID-19, ZEN

recently announced exclusive worldwide rights to commercialize rapid, saliva-based COVID-19 antigen testing technology in partnership with McMaster University. This technology is exceptionally accurate (similar to current PCR tests), saliva-based, affordable, scalable and provides results in under 10 minutes. It appears we aren't going to rid ourselves of this pesky virus anytime soon. So perhaps the best solution to getting on with some semblance of normal is accurate, rapid testing.

Being an optimist and looking beyond COVID-19 and hopefully no other mutation or pathogens running amok in public, we find that ZEN has developed a stable diesel fuel additive, which increased the performance of diesel fuel by up to 10% in initial testing. Greg Fenton, ZEN CEO commented: "With global market estimates for diesel fuel alone near \$1 trillion, the size of the challenge to reduce emissions from this level of demand is massive, but so is the opportunity for novel solutions to help us be more efficient in our usage." Regardless of whether you want zero emissions tomorrow, as long as everyone continues to order stuff off Amazon and you want fresh fruit in your grocery store, diesel demand is going to be with us for a while. So rather than be an environmental zealot, why not embrace solutions that help reduce emissions in the interim until we can finally achieve our ultimate goal. Which is a good segue into research ZEN is doing into lower-cost, reduced weight, higher performance and capacity energy storage applications by developing graphene-wrapped silicon anodes for Li-ion batteries.

Then there's the classic stereotype of nanomaterials making everything better. ZEN has its fingers in corrosion protective coating for reduced corrosion and enhanced longevity for steel. Polymers that enhance strength, longevity, and conductivity that can be used as versatile replacements for metallic electromagnetic shields. There's also enhanced strength and electrical conductivity aluminum for the

automotive industry and enhanced strength and longevity cement based composites for the construction industry. I'm probably missing something but you get the picture.

On a final note, on June 16th ZEN and Trebor Rx Corp. provided an update on the Health Canada review process for the ZENGuard™-enhanced, ASTM level 3 surgical mask. Clearly, the sooner they can get approvals and get mask production underway, the sooner they can start to realize the revenue from the Trebor agreement signed in November 2020 or a minimum of 100 million masks/filters. As a prospective investor, this is the news I'm eagerly awaiting.

Greg Fenton on how ZEN Graphene's disease detection technology will "revolutionize the way testing is done"

In a recent InvestorIntel interview, Tracy Weslosky speaks with Greg Fenton, CEO and Director of ZEN Graphene Solutions Ltd. (TSXV: ZEN) about ZEN's exclusive worldwide rights to commercialize rapid, saliva-based COVID-19 antigen testing technology announced yesterday

In this InvestorIntel interview, which may also be viewed on YouTube ([click here to subscribe to the InvestorIntel Channel](#)), Greg went on to say that this saliva-based test is exceptionally accurate, similar to current PCR tests, and will

“revolutionize the way testing is done”. Affordable, easy to use, scalable and provides results in under 10 minutes, Greg comments that this technology has the ability “to allow economies to reopen.” Tracy then asks the critical question with “will you be able to test for anything?”

To find out – watch the full interview, [click here](#)

About ZEN Graphene Solutions Ltd.

ZEN is a next-gen nanomaterials technology company developing and commercializing technologies that help protect people and the environment. ZEN is currently focused on commercializing **ZEN Guard™**, a patent pending graphene-based coating with 99% antimicrobial activity, including against COVID-19, and the potential to use similar graphene compounds as pharmaceutical products against infectious diseases. The company has a significant R&D pipeline with an interest in monomers, polymers, metal alloys, corrosion coatings, biosensors along with the production of graphene oxide and graphene quantum dots. Additionally, the company owns the unique Albany Graphite Project which provides the company with a potential competitive advantage in the graphene market. Labs in Japan, UK, Israel, USA, and Canada have independently demonstrated that ZEN’s Albany Pure™ Graphite is an ideal precursor material that easily converts (exfoliates) to graphene, using a variety of mechanical, chemical, and electrochemical methods.

To learn more about ZEN Graphene Solutions Ltd., [click here](#)

Disclaimer: ZEN Graphene Solutions Ltd. is an advertorial member of InvestorIntel Corp.

This interview, which was produced by InvestorIntel Corp. (IIC) does not contain, nor does it purport to contain, a summary of all the material information concerning the “Company” being interviewed. IIC offers no representations

or warranties that any of the information contained in this interview is accurate or complete.

This presentation may contain “forward-looking statements” within the meaning of applicable Canadian securities legislation. Forward-looking statements are based on the opinions and assumptions of management of the Company as of the date made. They are inherently susceptible to uncertainty and other factors that could cause actual events/results to differ materially from these forward-looking statements. Additional risks and uncertainties, including those that the Company does not know about now or that it currently deems immaterial, may also adversely affect the Company’s business or any investment therein.

Any projections given are principally intended for use as objectives and are not intended, and should not be taken, as assurances that the projected results will be obtained by the Company. The assumptions used may not prove to be accurate and a potential decline in the Company’s financial condition or results of operations may negatively impact the value of its securities. Prospective investors are urged to review the Company’s profile on www.Sedar.com and to carry out independent investigations in order to determine their interest in investing in the Company.

If you have any questions surrounding the content of this interview, please email info@investorintel.com.

ZEN Graphene’s Dr Francis

Dube on the ZENGuard™ enhanced surgical masks and the development of a new fuel additive

In a recent InvestorIntel interview, Tracy Weslosky speaks with Dr. Francis Dube, Executive Chairman of ZEN Graphene Solutions Ltd. (TSXV: ZEN) about ZEN's recent milestones including the successful inhalation safety testing of the ZENGuard™ enhanced surgical masks and the development of a new fuel additive.

In this InvestorIntel interview, which may also be viewed on YouTube (click here to subscribe to the InvestorIntel Channel), Dr. Dube starts by explaining the impact of the ZENGuard™ enhanced surgical masks and submission to Health Canada news release. He discusses how their market is with the medical industry and how this demand will only grow.

Equally as interesting to host Tracy was the potential to attract ESG funds with the new fuel additive announcement. Francis explains that ZEN has developed a stable diesel fuel additive, which increased the performance of diesel fuel by up to 10% in initial testing. He states that "If we can make diesel fuel 10-20% better we are going to have a significant impact on the amount of emissions...we think we can make a difference from an environmental standpoint."

To watch the full interview, click here

About ZEN Graphene Solutions Ltd.

ZEN is a next-gen nanomaterials technology company developing and commercializing technologies that help protect people and

the environment. ZEN is currently focused on commercializing ZEN Guard™, a patent pending graphene-based coating with 99% antimicrobial activity, including against COVID-19, and the potential to use similar graphene compounds as pharmaceutical products against infectious diseases. The company has a significant R&D pipeline with an interest in monomers, polymers, metal alloys, corrosion coatings, biosensors along with the production of graphene oxide and graphene quantum dots. Additionally, the company owns the unique Albany Graphite Project which provides the company with a potential competitive advantage in the graphene market. Labs in Japan, UK, Israel, USA, and Canada have independently demonstrated that ZEN's Albany Pure™ Graphite is an ideal precursor material that easily converts (exfoliates) to graphene, using a variety of mechanical, chemical, and electrochemical methods.

To learn more about ZEN Graphene Solutions Ltd., [click here](#)

Disclaimer: ZEN Graphene Solutions Ltd. is an advertorial member of InvestorIntel Corp.

This interview, which was produced by InvestorIntel Corp. (IIC) does not contain, nor does it purport to contain, a summary of all the material information concerning the "Company" being interviewed. IIC offers no representations or warranties that any of the information contained in this interview is accurate or complete.

This presentation may contain "forward-looking statements" within the meaning of applicable Canadian securities legislation. Forward-looking statements are based on the opinions and assumptions of management of the Company as of the date made. They are inherently susceptible to uncertainty and other factors that could cause actual events/results to differ materially from these forward-looking statements. Additional risks and uncertainties, including

those that the Company does not know about now or that it currently deems immaterial, may also adversely affect the Company's business or any investment therein.

Any projections given are principally intended for use as objectives and are not intended, and should not be taken, as assurances that the projected results will be obtained by the Company. The assumptions used may not prove to be accurate and a potential decline in the Company's financial condition or results of operations may negatively impact the value of its securities. Prospective investors are urged to review the Company's profile on www.Sedar.com and to carry out independent investigations in order to determine their interest in investing in the Company.

If you have any questions surrounding the content of this interview, please email info@investorintel.com.